These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18551912)

  • 1. [Current aspects in the therapy of renal cell cancer].
    Heynemann H
    Praxis (Bern 1994); 2008 Apr; 97(8):427-30. PubMed ID: 18551912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.
    Stachowicz-Stencel T; Bien E; Balcerska A; Godzinski J; Synakiewicz A; Perek-Polnik M; Kurylak A; Pietras W; Kuzmicz M; Mizia-Malarz A; Rybczynska A; Nurzynska-Flak J
    Klin Padiatr; 2011 May; 223(3):138-41. PubMed ID: 21509711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
    Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
    Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Node positive renal cell cancer. Who can be helped?
    Messing EM
    Eur Urol; 2007 Jun; 51(6):1477-8. PubMed ID: 17240037
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 10. Nephron-sparing surgery for renal cell carcinoma in the solitary kidney.
    Berdjis N; Hakenberg OW; Novotny V; Manseck A; Oehlschläger S; Wirth MP
    Scand J Urol Nephrol; 2007; 41(1):10-3. PubMed ID: 17366096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic partial nephrectomy.
    Schwaibold HE; Stolzenburg JU
    Arch Ital Urol Androl; 2009 Jun; 81(2):72-5. PubMed ID: 19760859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor size and nephron-sparing surgery: does it still matter?
    Bensalah K; Crépel M; Patard JJ
    Eur Urol; 2008 Apr; 53(4):691-3. PubMed ID: 18060683
    [No Abstract]   [Full Text] [Related]  

  • 13. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Harshman LC; Srinivas S
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
    Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
    Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive nephrectomy: past, present and future.
    Galazi M; Rodriguez-Vida A; Josephides E; Chau NM; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):271-7. PubMed ID: 24392671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgical treatment for renal cell carcinoma].
    Roos FC; Rübben H; Stief C; Stöckle M; Thüroff JW
    Aktuelle Urol; 2010 Jul; 41(4):252-6. PubMed ID: 20661841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
    Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
    Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: a single-centre experience.
    Parra J; Drouin SJ; Hupertan V; Comperat E; Bitker MO; Rouprêt M
    Eur J Surg Oncol; 2011 May; 37(5):422-8. PubMed ID: 21330093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
    Bex A; Powles T
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.